Print ISSN:-2581-5555

Online ISSN:-2456-9542

CODEN : IIJCDU

Article History

Received : 12-06-2021

Accepted : 14-07-2021



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 513

PDF Downloaded: 465


A review on current strategies and emerging treatments in management of silicosis: An ayurveda perspective


Full Text PDF Share on Facebook Share on Twitter


Review Article

Author Details : Dhanashri Tikaram Jawal, Shubhada V Mangrulkar*, Prasad Sherekar, Dinesh R Chaple

Volume : 6, Issue : 2, Year : 2021

Article Page : 40-47

https://doi.org/10.18231/j.ijcaap.2021.008



Suggest article by email

Get Permission

Abstract

Background: Silicosis is a possibly deadly, irreversible, fibrotic pneumonic sickness that may create resulting to the inward breath of a lot of silica dust over the long haul. As a rule, silicosis just creates resulting to significant word related presentations. The sickness has a long idleness period and may clinically present as an intense, quickened, or ongoing infection.
Main Body: In this audit the medicines that can lessen the aggravation and scarring in which are as nodular injuries in the upper projections of the lungs. The principle point of audit is to the likely home grown treatment for silicosis. This survey zeroed in on different medicines which incorporate natural plants, neutraceuticals, polyherbals, and herbominerals and furthermore cell based treatment for silicosis.
Conclusion: From that review we presume that the natural treatment which is utilized in treatment of silicosis is potential treatments which incorporate huge quantities of home grown plants, polyherbals, neutraceuticals and herbominerals likewise incorporate the new treatment for silicosis is the cell based treatment.

Keywords: Silicosis, Occupational silicosis, Silicoproteinous, Neutraceuticals, herbominerals



How to cite : Jawal D T, Mangrulkar S V, Sherekar P, Chaple D R, A review on current strategies and emerging treatments in management of silicosis: An ayurveda perspective. IP Int J Compr Adv Pharmacol 2021;6(2):40-47


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.